Antibiotics

It is produced by the strain of Micronconospora sp. SF2364. It has weak effect against gram-positive bacteria. Mice inoculated with leukemic P388 cells were given 2.1 and 1.0 mg/kg, which extended the survival time by 96% and 69% compared with the control group.

It is produced by the strain of Nocardia sp. SC 113, Act. sp. 69-209B-89. It has the effect against aerobic and anaerobic bacteria, and has anti-Gram-positive bacteria, Gram-negative bacteria and fungal effects but no anti-Candida albicans effect. The antibacterial activity of Siderochelin A is weaker than iron chelating agent Apoferrosamine. Fe2+, Fe3+, CO2+ and Zn2+ have antagonistic effects on Siderochelin A.

It is produced by the strain of Nocardia sp. SC 113, Act. sp. 69-209B-89. It has only weak effect against individual strains, such as E. coli.

It is produced by the strain of Act. sp. 69-209B-89. It has only weak effect against individual strains, such as E. coli.

It is produced by the strain of Streptomyces antibioticus Tu 6040. It has moderate anti-gram-positive bacteria activity and has inhibitory effect on a variety of tumor cells. It inhibits HMO2, MCF7 and HEP G2 cells with GI50 (μmol/L) of 0.30, 5.6 and 8.5, respectively.

It is produced by the strain of Streptomyces antibioticus Tu 6040. It has moderate anti-gram-positive bacteria activity and has inhibitory effect on a variety of tumor cells. It inhibits HMO2, MCF7 and HEP G2 cells with GI50 (μmol/L) of 0.50, 0.95 and >50, respectively.

It is produced by the strain of Sirodesmum diversum. It has antiviral effect.

It is produced by the strain of Sirodesmum diversum. It has antiviral effect.

It is produced by the strain of Sirodesmum diversum. It has antiviral effect.

It is an aminoglycoside antibiotic produced by the strain of Pseudomonas sorbicinii nov. sp. It has anti-gram-positive and negative bacteria effects. Sorbistin A1 has moderate antibacterial activity, but it is stronger than Sorbistin A2 and B. Sorbistin A1 has no anti-anaerobic effect, but it has anti-plant pathogenic bacteria effect. It has the property of resisting some aminoglycoside antibiotic passivase, so it has antibacterial effect on some strains resistant to aminoglycoside antibiotic.

It is an aminoglycoside antibiotic produced by the strain of Pseudomonas sorbicinii nov. sp. It has anti-gram-positive and negative bacteria effects. Sorbistin A1 has moderate antibacterial activity, but it is stronger than Sorbistin A2 and B.

It is an aminoglycoside antibiotic produced by the strain of Pseudomonas sorbicinii nov. sp. It has anti-gram-positive and negative bacteria effects. Sorbistin A1 has moderate antibacterial activity, but it is stronger than Sorbistin A2 and B. Sorbistin B has no anti-anaerobic effect, but it has anti-plant pathogenic bacteria effect.

It is produced by the strain of Penicillium chrysogenu SC 13887. It has weak to moderate effect against Gram-positive and Gram-negative bacteria.

It is produced by the strain of Str. sparsogenes SN 2325. It is a novel mammalian cell proliferation effector that converts the transformed phenotype of Rous sarcoma virus-infected NRK cells to a normal phenotype.

It is produced by the strain of Str. sparsogenes SN 2325. It is a novel mammalian cell proliferation effector that converts the transformed phenotype of Rous sarcoma virus-infected NRK cells to a normal phenotype. It has weak antimicrobial activity (such as Escherichia coli) but has no effect on staphylococcus aureus, candida albicans and staphylococcus grayi.

It is produced by the strain of Pseudomonas fluorescens YK-437. In vitro it has the effect of anti-pyomonas aeruginosa, alkali-producing faecal bacteria, acinetobacter calcium acetate and staphylococcus aureus. It also has antibacterial effect on Staphylococcus aureus and Pseudomonas aeruginosa resistant to methicillin, streptomycin, kanamycin, gentamicin, erythromycin, lincomycin, etc. It is used in mice infected with Staphylococcus aureus, Streptococcus pyogenes and E. coli O-111 with ED50 (mg/kg, subcutaneous) of 1.31, 8.13 and 67.2, respectively.

It is produced by the strain of Pseudomonas fluorescens YK-437. In vitro it has the effect of anti-pyomonas aeruginosa, alkali-producing faecal bacteria, acinetobacter calcium acetate and staphylococcus aureus. It also has antibacterial effect on Staphylococcus aureus and Pseudomonas aeruginosa resistant to methicillin, streptomycin, kanamycin, gentamicin, erythromycin, lincomycin, etc. It is used in mice infected with Staphylococcus aureus, Streptococcus pyogenes and E. coli O-111 with ED50 (mg/kg, subcutaneous) of 0.35, 8.84 and 27.3, respectively.

It is produced by the strain of Pseudomonas fluorescens YK-437. In vitro it has the effect of anti-pyomonas aeruginosa, alkali-producing faecal bacteria, acinetobacter calcium acetate and staphylococcus aureus. It also has antibacterial effect on Staphylococcus aureus and Pseudomonas aeruginosa resistant to methicillin, streptomycin, kanamycin, gentamicin, erythromycin, lincomycin, etc. It is used in mice infected with Staphylococcus aureus and E. coli O-111 with ED50 (mg/kg, subcutaneous) of 12.5 and 50, respectively.

It is produced by the strain of Pseudomonas fluorescens YK-437. In vitro it has the effect of anti-pyomonas aeruginosa, alkali-producing faecal bacteria, acinetobacter calcium acetate and staphylococcus aureus. It also has antibacterial effect on Staphylococcus aureus and Pseudomonas aeruginosa resistant to methicillin, streptomycin, kanamycin, gentamicin, erythromycin, lincomycin, etc. It is used in mice infected with Staphylococcus aureus and E. coli O-111 with ED50 (mg/kg, subcutaneous) of 1.82 and 55.9, respectively.

It is an aromatic derivative of antibiotic produced by the strain of Str. albospinus M-750-G1. It has anti-mycobacterium and fungal effects, and the serum does not affect its effect on Cryptococcus yeast and psoriasis mold. It inhibits cell culture for Yoshida sarcoma with IC50 of 1.5 μg/mL. Mice can tolerate 125 mg/kg of Spinamycin intraperitoneal injection.